{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:12:41Z","timestamp":1789053161699,"version":"build-2803163510"},"reference-count":68,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Type 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and share multiple causal associations. Both conditions have an alarmingly increasing incidence and lead to multiple complications, which have an impact on a variety of organs and systems, such as the kidneys, eyes, and nervous and cardiovascular systems, or may cause metabolic disruptions. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i), as an antidiabetic class with well-established cardiovascular benefits, and its class members have also been studied for their presumed effects on steatosis and fibrosis improvement in patients with NAFLD or non-alcoholic steatohepatitis (NASH). The MEDLINE and Cochrane databases were searched for randomized controlled trials examining the efficacy of SGLT2-i on the treatment of NAFLD\/NASH in patients with T2DM. Of the originally identified 179 articles, 21 articles were included for final data analysis. Dapagliflozin, empagliflozin, and canagliflozin are some of the most used and studied SGLT2-i agents which have proven efficacy in treating patients with NAFLD\/NASH by addressing\/targeting different pathophysiological targets\/mechanisms: insulin sensitivity improvement, weight loss, especially visceral fat loss, glucotoxicity, and lipotoxicity improvement or even improvement of chronic inflammation. Despite the considerable variability in study duration, sample size, and diagnostic method, the SGLT2-i agents used resulted in improvements in non-invasive markers of steatosis or even fibrosis in patients with T2DM. This systematic review offers encouraging results that place the SGLT2-i class at the top of the therapeutic arsenal for patients diagnosed with T2DM and NAFLD\/NASH.<\/jats:p>","DOI":"10.3390\/medicina59061136","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T01:35:30Z","timestamp":1686620130000},"page":"1136","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8957-5980","authenticated-orcid":false,"given":"Ioana-Cristina","family":"Bica","sequence":"first","affiliation":[{"name":"The Doctoral School of \u201cCarol Davila\u201d, University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0085-6872","authenticated-orcid":false,"given":"Roxana Adriana","family":"Stoica","sequence":"additional","affiliation":[{"name":"The Department of Diabetes, Nutrition and Metabolic Diseases, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 030167 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-7441","authenticated-orcid":false,"given":"Teodor","family":"Salmen","sequence":"additional","affiliation":[{"name":"The Doctoral School of \u201cCarol Davila\u201d, University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-5254","authenticated-orcid":false,"given":"Andrej","family":"Jane\u017e","sequence":"additional","affiliation":[{"name":"The Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center, The Medical Faculty, The University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2354-6279","authenticated-orcid":false,"given":"\u0160pela","family":"Vol\u010dan\u0161ek","sequence":"additional","affiliation":[{"name":"The Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center, The Medical Faculty, The University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje","family":"Popovic","sequence":"additional","affiliation":[{"name":"The Clinic for Endocrinology, Diabetes and Metabolic Disorders, The Clinical Centre of Vojvodina, The Medical Faculty, The University of Novi Sad, 21137 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-3298","authenticated-orcid":false,"given":"Emir","family":"Muzurovic","sequence":"additional","affiliation":[{"name":"The Department of Internal Medicine, The Endocrinology Section, The Clinical Center of Montenegro, The Faculty of Medicine, The University of Montenegro, 81000 Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9549-8504","authenticated-orcid":false,"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[{"name":"The Department of Diabetes, Nutrition and Metabolic Diseases, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 030167 Bucharest, Romania"},{"name":"School of Medicine, Promise Department, University of Palermo, 90100 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0555-526X","authenticated-orcid":false,"given":"Anca Pantea","family":"Stoian","sequence":"additional","affiliation":[{"name":"The Department of Diabetes, Nutrition and Metabolic Diseases, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 030167 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_2","unstructured":"World Health Organization (2023, February 02). Diabetes. Available online: https:\/\/www.who.int\/health-topics\/diabetes#tab=tab_1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100089","DOI":"10.1016\/j.endmts.2021.100089","article-title":"The global epidemiology of nonalcoholic steato-hepatitis (NASH) and associated risk factors\u2014A targeted literature review","volume":"3","author":"Dufour","year":"2021","journal-title":"Endocr. Metab. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Dalbeni, A., Beatrice, G., Cappelli, D., and Gomez-Peralta, F. (2022). Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. J. Clin. Med., 11.","DOI":"10.3390\/jcm11040968"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: Results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","article-title":"Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Review of Shared Cardiometabolic Risk Factors","volume":"79","author":"Peng","year":"2022","journal-title":"Hypertension"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cld.1017","article-title":"Nonalcoholic Fatty Liver Disease and Cardiovascular Disease","volume":"17","author":"Przybyszewski","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis Se-verity as a Determinant of Cause-Specific Mortality in Patients with Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study","volume":"155","author":"Wong","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"ref_14","first-page":"S24","article-title":"Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!","volume":"34","author":"Katsiki","year":"2022","journal-title":"Clin. Investig. Arterioscler."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An Update on SGLT2 Inhibitors for the Treatment of Diabetes Mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_17","first-page":"199","article-title":"Effects of SGLT2 inhibitors on weight loss in pa-tients with type 2 diabetes mellitus","volume":"21","author":"Ribola","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12325-021-01994-2","article-title":"Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape","volume":"39","author":"Mende","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_19","unstructured":"(2023, February 25). View of Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. Available online: https:\/\/journals.library.ualberta.ca\/jpps\/index.php\/JPPS\/article\/view\/29831\/21427."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106679","DOI":"10.1016\/j.phrs.2023.106679","article-title":"Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)","volume":"189","author":"Rizzo","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10742484221146371","DOI":"10.1177\/10742484221146371","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide\/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity\/Metabolic Syndrome, Prediabetes\/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence","volume":"27","author":"Mikhailidis","year":"2022","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_25","first-page":"2387","article-title":"Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review)","volume":"20","author":"Bica","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"117090","DOI":"10.1016\/j.lfs.2019.117090","article-title":"Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review","volume":"240","author":"Yaribeygi","year":"2019","journal-title":"Life Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00795-022-00334-9","article-title":"Hepatic expression of sodium\u2013glucose cotransporter 2 (SGLT2) in patients with chronic liver disease","volume":"55","author":"Nakano","year":"2022","journal-title":"Med. Mol. Morphol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/14712598.2015.1067299","article-title":"Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pilot study","volume":"15","author":"Rizvi","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2130926","DOI":"10.1001\/jamanetworkopen.2021.30926","article-title":"Overcoming Therapeutic Inertia in Type 2 Diabetes Care\u2014Timing, Context, and Appropriateness of Treatment Intensification","volume":"4","author":"McCoy","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_30","unstructured":"(2023, February 20). Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Available online: http:\/\/www.prisma-statement.org\/."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study with 8-Week Treatment in Type 2 Diabetes Patients","volume":"42","author":"Honka","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_32","first-page":"61","article-title":"Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy","volume":"24","author":"Maaske","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/dom.13907","article-title":"Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes","volume":"22","author":"Gastaldelli","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdi.13457","article-title":"Favorable effect of sodium\u2013glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone","volume":"12","author":"Cho","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/dom.14004","article-title":"Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes","volume":"22","author":"Johansson","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3164\/jcbn.20-129","article-title":"Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: A prospective randomized study","volume":"68","author":"Tobita","year":"2021","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/dom.14319","article-title":"Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial","volume":"23","author":"Harreiter","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial","volume":"43","author":"Kahl","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: The EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Elhini, S.H., Wahsh, E.A., Elberry, A.A., El Ameen, N.F., Saedii, A.A., Refaie, S.M., Elsayed, A.A., and Rabea, H.M. (2022). The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals, 15.","DOI":"10.3390\/ph15121516"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s13340-016-0302-y","article-title":"The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus","volume":"8","author":"Bando","year":"2017","journal-title":"Diabetol. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study","volume":"20","author":"Shibuya","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Han, E., Lee, Y.-H., Lee, B.-W., Kang, E.S., and Cha, B.-S. (2020). Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010259"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin Improves the Hepatic Outcomes of Patients with Diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e001990","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): A randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants with Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e00910","DOI":"10.1002\/prp2.910","article-title":"Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea","volume":"10","author":"Yang","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneph.2016.159","article-title":"Acute kidney injury from SGLT2 inhibitors: Potential mechanisms","volume":"12","author":"Hahn","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2020.05.014","article-title":"We Can Finally Stop Worrying about SGLT2 Inhibitors and Acute Kidney Injury","volume":"76","author":"Sridhar","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"973129","DOI":"10.3389\/fcvm.2022.973129","article-title":"Risk of hypovolemia associated with sodium\u2013glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials","volume":"9","author":"Rong","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jacc.2021.07.050","article-title":"Low Blood Pressure and Managing Drugs in HF","volume":"78","author":"Girerd","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabres.2017.04.017","article-title":"Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials","volume":"130","author":"Monami","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of Canagliflozin on Fracture Risk in Patients with Type 2 Diabetes Mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_65","unstructured":"The Nuffield Department of Population Health Renal Studies Group and and theSGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (2022). Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet, 400, 1788\u20131801."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/met.2015.0018","article-title":"Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease","volume":"13","author":"Ercin","year":"2015","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/dom.14670","article-title":"Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes","volume":"24","author":"Kahl","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Riazi, K., Raman, M., Taylor, L., Swain, M.G., and Shaheen, A.A. (2019). Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?. Nutrients, 11.","DOI":"10.3390\/nu11122878"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1136\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:53:37Z","timestamp":1760126017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":68,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["medicina59061136"],"URL":"https:\/\/doi.org\/10.3390\/medicina59061136","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}